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Abstract
/st> Molecular factors modulating angiogenic responses are dysregulated in patients with MCTD and
SSc with increases of VEGF in MCTD and SSc and selective upregulation of endostatin in MCTD.
Furthermore, high serum levels of VEGF might characterise patients with MCTD with a more severe
course of the disease with increased prevalence of PAH and myositis.
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Abstract 
Objective: Vascular disease is common in mixed connective tissue disease (MCTD). The 
aim of the present study was to investigate, whether dysbalance of angiogenic and angiostatic 
factors occurs in MCTD.   
Methods: Thirty-eight patients with MCTD and 40 patients with systemic sclerosis (SSc) for 
comparison were included. Four centers contributed to this cross-sectional analysis. Sixty-six 
healthy volunteers were used as controls. The serum levels of vascular endothelial growth 
factor (VEGF), basic fibroblast growth factor (bFGF) and endostatin were determined by 
ELISA. For comparisons between controls and MCTD patients and detection of associations 
of serum levels with dichotomous clinical parameters in MCTD patients the Mann–Whitney 
test was used.  
Results: Serum levels of the angiogenic factor VEGF were significantly elevated in patients 
with MCTD and SSc. We also detected significantly increased levels of the angiostatic factor 
endostatin in MCTD, but not in SSc. No differences were observed for bFGF. Levels of 
VEGF were higher in MCTD patients with pulmonary arterial hypertension (PAH), 
acrosclerosis and myositis. In multivariate linear regression analysis, an additive model of 
PAH, myositis and lymphadenopathy accounted for 79 % of the variability of the VEGF 
levels (r = 0.889).  
Conclusion: Molecular factors modulating angiogenic responses are dysregulated in patients 
with MCTD and SSc with increases of VEGF in MCTD and SSc and selective upregulation of 
endostatin in MCTD. Furthermore, high serum levels of VEGF might characterize MCTD 
patients with a more severe course of the disease with increased prevalence of PAH and 
myositis.   
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Introduction 
Mixed connective tissue disease (MCTD) was first described in 1972 by Sharp and 
colleagues as a connective tissue disease with features of systemic lupus erythematosus 
(SLE), systemic sclerosis (SSc) and polymyositis characterized by the presence of high titres 
of anti-U1-RNP autoantibodies [1]. A high prevalence of arthritis resembling rheumatoid 
arthritis (RA) was later observed in patients with MCTD. Common manifestations are 
myositis, arthritis, puffy hands, oesophageal dysfunction and reduced DLCO on lung function 
testing [2]. However, the most common and most severe clinical manifestations do not result 
from inflammation or fibrosis, but from vascular alterations [3]. The pattern of vascular 
involvement resembles that of SSc with potential involvement of pulmonary arteries and 
frequent microvascular changes. PAH is common in MCTD. While right heart catheterization 
data are missing, the prevalence of PAH based on data from echocardiography has been 
suggested to be as high as 23 % [2], and PAH is a major cause of death in patients with 
MCTD. Raynaud’s phenomenon occurs in 75 – 96 % of patients and is observed early in the 
course of the disease [2]. Although the vascular changes in MCTD are well documented, the 
underlying pathophysiology remains obscure. 
The formation of new vessels in the adult can occur by angiogenesis or vasculogenesis 
[4], both of which are perturbed in rheumatic diseases such as SSc, SLE and RA [5, 6]. 
Angiogenesis and vasculogenesis are highly complex, multi-step processes. To avoid an 
uncontrolled formation of new vessels, all steps are controlled by an array of angiogenic and 
angiostatic factors [7]. However, dysregulation of one of these factors might have profound 
impact and result in severe defects of angiogenesis and vasculogenesis [6]. Vascular 
endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) have been 
characterized as key molecules for the formation of new vessels. VEGF regulates several 
steps of angiogenesis and vasculogenesis including proliferation, survival and migration of 
endothelial cells and precursor cells [7]. The biological effects of VEGF are dose- and time 
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dependent. As indicated by transgenic mice overexpressing VEGF, the uncontrolled 
overexpression of VEGF might have deleterious rather than beneficial effects as it may result 
in the formation of irregular vessels with impaired blood flow [8]. Similar to VEGF, bFGF 
stimulates proliferation, migration and differentiation of endothelial cells in vitro and in vivo 
[7, 9]. Endostatin is a very potent inhibitor of angiogenesis that is generated upon cleavage of 
collagen type XVIII. Endostatin inhibits angiogenesis by reducing endothelial cell 
proliferation and migration, potentially by inhibiting membrane type 1 matrix 
metalloproteinase and matrix metalloproteinase-2 [7, 10]. 
The microvascular alterations in MCTD might be caused by a dysbalance between 
angiogenic and angiostatic factors or by an uncontrolled overexpression of angiogenic factors. 
The aim of the present study was to analyze, whether a decrease of the angiogenic factors 
VEGF and bFGF and an increase of the angiostatic factor endostatin contribute to the vascular 
disease in MCTD, and whether the levels of VEGF, bFGF or endostatin correlate with the 
disease phenotype of MCTD. 
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Material and methods 
MCTD Patients  
Thirty-eight consecutive, unselected patients with MCTD were recruited at the 
Department of Internal Medicine 3 and Institute for Clinical Immunology of the University of 
Erlangen-Nuremberg, at the Department of Rheumatology of the University Hospital Zurich, 
at the Division of Rheumatology of the Medical University of Vienna and at the Department 
of Internal Medicine and Rheumatology of the Justus-Liebig-University of Giessen. The 
MCTD cohort comprised 34 women and 4 men. The median age was 47 years (range 18-78 
years). All patients fulfilled the criteria of Alarcon-Segovia for MCTD [11]. The criteria of 
Alarcon-Segovia (Table 1) were chosen, because of their very high specificity for MCTD [12, 
13]. Patients fulfilling classification criteria for other connective tissue diseases were 
excluded from the study as were patients fulfilling classification criteria for two connective 
tissue diseases at the same time (“overlap syndromes”). The control group consisted of 44 
women and 22 men with a median age of 39 years (range 19 – 74 years). All patients and 
controls were of Caucasian origin and signed a consent form approved by the local ethical 
committees. Since MCTD and control group significantly differed in their median age by 8 
years, and age could not be precluded to influence the levels of growth factors, a selection of 
control and of MCTD group matched by age categories in 5-years steps was drawn for 
additional analyses. These age-matched samples consisted of n=30 patients with a common 
median age of 46 years (range MCTD 18-71 years, range controls 19-74 years). 
 
SSc patients 
For comparison, twenty patients with limited cutaneous SSc (lSSc) and 20 patients 
with diffuse cutanous SSc (dSSc) were recruited at the Department of Internal Medicine 3 and 
Institute for Clinical Immunology of the University of Erlangen-Nuremberg. Both groups 
were matched for age and sex. The SSc cohort comprised 34 women and 4 men. The median 
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age was 46 years (range 19-77 years). All patients fulfilled the criteria of LeRoy [14]. Patients 
fulfilling classification criteria for other connective tissue diseases were excluded. 
  
Clinical assessment  
An extensive clinical profile was established for each MCTD patient. The 
characteristics of the patients are summarized in Table 2. Muscular involvement was analyzed 
by clinical assessment of muscle strength, determination of serum creatine kinase (CK), 
electromyography and muscle biopsy. In accordance with the criteria of Alarcon-Segovia, 
myositis was diagnosed, when at least twofold elevated serum CK levels and characteristic 
electromyographic changes were detected or when myositis was proven histologically. In this 
cohort, myositis was confirmed by muscle biopsy in 14 of 21 MCTD patients with myositis. 
The presence of joint involvement with arthritis, arthralgias, morning stiffness and rheumatoid 
nodules were evaluated by trained rheumatologists. Patients were also evaluated by clinical 
examination for the presence of lymphadenopathy, malar rash, alopecia, Raynaud’s 
phenomenon, puffy hands and acrosclerosis. Interstitial pulmonary involvement was 
examined in all patients by the carbon monoxide diffusion capacity using the single-breath 
method standardized for hemoglobin, by determination of the forced vital capacity (FVC) and 
by x-ray. Suspected interstitial lung disease was further evaluated by high resolution 
computed tomography (HRCT). Echocardiography was performed to screen for PAH, and 
sPAP was calculated. As patients with elevated sPAP cannot be automatically considered as 
P(A)H patients, PAH was diagnosed in patients with a mean pulmonary arterial pressure of > 
25 mmHg at rest with a wedge pressure of ≤ 15 mmHg on right heart catheterization. Upon 
clinical suspicion, the presence or absence of pleuritis and pericarditis was analyzed by 
ultrasound, x-ray or HRCT. In patients with clinical symptoms suspicious of oesophageal 
involvement, the incidence of oesophageal dysmotility was determined by barium swallow or 
manometry. Trigeminal neuralgia was diagnosed according to the International Headache 
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Society criteria. Antinuclear antibodies were determined by immunofluorescence according to 
local practice and U1-RNP-antibodies antibodies were determined by ELISA 
(Erlangen/Zurich: Anti-RNP 70 Kit 632, Orgentec, Mainz, Germany; Giessen: Anti-
nRNP/Sm-ELISA, Euroimmun, Lübeck, Germany; Vienna: ELiATM U1RNP Kit, Phadia, 
Freiburg, Germany).  
 
Enzyme linked Immunosorbent Assay (ELISA) 
After obtaining informed consent, blood samples were drawn from patients as well as 
from healthy controls from the antecubital vein. Samples were centrifuged, and the obtained 
sera were stored in aliquots at -80°C until analysis. Serum levels of VEGF, bFGF and 
endostatin were measured using commercially available colorimetric sandwich ELISAs (R&D 
Systems, Minneapolis, USA) as described [15]. Concentrations were calculated using a 
standard curve generated with specific standards provided by the manufacturer. The ELISA 
for VEGF recognizes human VEGF165 with cross-reactivity to VEGF121, but not to factors 
related to VEGF such as human placental growth factor and platelet-derived growth factor. 
Inter-assay and intra-assay variances were less than 10 %. The assay for bFGF showed 
minimal cross-reactivity to FGF-4 (0.02 %), but not to other factors related to bFGF such as 
acidic fibroblast growth factor. The assay for endostatin did not show any cross-reactivity 
with World Health Organization standards for any human cytokine.  
 
Statistical analysis 
 Statistical analysis was performed by the biostatistician of the group (DH). Data are 
expressed as median and interquartile range (IQR). Differences in serum levels of growth 
factors were tested between groups composed by categorical parameters to assess association 
of disease parameters with serum levels of VEGF, bFGF and endostatin. The Mann Whitney 
U-test was used to compare two groups. To assess correlation of continuous variables with the 
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levels of the analyzed growth factors, Pearson’s and Spearman’s rank correlation coefficients 
were calculated. P-values < 0.05 were considered statistically significant. Since we tested 
many variables in a small data set, multivariate linear regression models were applied in a 
stepwise forward and stepwise backward manner to determine a robust combination of 
variables predicting the levels of VEGF in MCTD patients. ROC analysis was used to identify 
a cut off for VEGF levels to predict PAH in MCTD patients. 
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Results 
Increased levels of circulating VEGF and endostatin in patients with MCTD 
Levels of the potent angiogenic growth factor VEGF were significantly increased in 
the blood of patients with MCTD (p=0.017). Interestingly, we also observed elevated levels of 
the anti-angiogenic mediator endostatin (p<0.001). Since we assumed a possible confounding 
by the differing age between groups, comparisons were repeated in the age-matched samples. 
But confirmative, VEGF levels were significantly increased in MCTD patients (median 218 
pg/ml; IQR 141 – 310 pg/ml) compared to healthy volunteers (median 120 pg/ml; IQR 67 – 
269 pg/ml) (p = 0.045) (Figure 1a). The levels of circulating endostatin were almost twice as 
high in MCTD patients (median 30600 pg/ml; IQR 25290 – 48040 pg/ml) as in controls 
(median 18840 pg/ml; IQR 6770 – 25490 pg/ml) of similar age (p < 0.001) (Figure 1b). No 
differences were detected for bFGF between patients with MCTD and controls (MCTD: 
median 64 pg/ml; IQR 14 – 180 pg/ml / controls: median 55 pg/ml; IQR 14 – 90 pg/ml) (p = 
0.80).  
For further comparison to other connective tissue diseases, we analyzed the levels of 
circulating VEGF and endostatin in an additional cohort of age- and sex matched SSc 
patients, which consisted of 20 patients with limited cutaneous SSc and 20 patients with 
diffuse cutaneous SSc. The mean levels of VEGF were higher in both SSc groups (dcSSc: 
median 351 pg/ml; IQR 96 – 802 pg/ml; lcSSc: median 310 pg/ml; IQR 75 – 624 pg/ml) than 
in patients with MCTD. However, this difference did not reach statistical significance (p = 
0.34). Similarly, the differences between diffuse and limited SSc were not significant (p = 
0.66). In contrast, the levels of endostatin were only elevated in patients with MCTD, but not 
in patients with lcSSc or dcSSc (dcSSc: median 15450 pg/ml; IQR 5960 – 27890 pg/ml; 
lcSSc: median 17230 pg/ml; IQR 8540 – 32410 pg/ml; healthy: median 18840 pg/ml; IQR 
6770 – 25490 pg/ml; p = 0.54 and p = 0.87, respectively). 
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Higher levels of VEGF in MCTD patients with acrosclerosis 
 Increased concentrations of VEGF have been reported by several independent 
investigators in patients with SSc [7, 16]. A subset of patients with MCTD also shows SSc-
like manifestations with skin fibrosis at the fingers and acrosclerosis. Consistent with the 
results in SSc patients, we measured elevated blood levels of VEGF in MCTD patients with 
acrosclerosis (median 282 pg/ml; IQR 220 – 492 pg/ml) compared to other MTCD patients 
(median 171 pg/ml; IQR 113 – 253 pg/ml) (p = 0.015) (Figure 2). In contrast, no association 
between the levels of bFGF or endostatin and acrosclerosis were observed. As all SSc patients 
had acrosclerosis, subanalysis was not possible in this cohort. There was no significant 
correlation with the modified Rodnan skin score in patients with SSc.  
 
Increased levels of VEGF in MCTD patients with myositis 
 High levels of VEGF correlated with the presence of myositis. Significantly increased 
levels of VEGF were measured in MTCD patients with myositis (median 261 pg/ml; IQR 195 
–492 pg/ml) compared to MCTD patients without myositis (median 144 pg/ml; IQR 105 – 
277 pg/ml) (p = 0.009) (Figure 3a). Consistent with the diagnosis of myositis, elevated levels 
of VEGF were also detected in patients with a history of at least twofold increased serum 
levels of CK (elevated CK: median 352 pg/ml; IQR 236 – 646 pg/ml / normal CK: median 
143 pg/ml; IQR 105 – 264 pg/ml) (p < 0.001) (Figure 3b). Interestingly, the increased levels 
of VEGF persisted even when the myositis was well controlled and CK levels had returned to 
normal, suggesting that increased levels of VEGF might be a risk marker rather than an 
activity marker. No associations between the presence of myositis or a history of elevated CK 
and the levels of bFGF or endostatin were observed.  
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Association between the levels of circulating VEGF and PAH in MCTD patients 
 VEGF has recently been implicated in the pathogenesis of PAH [17]. We found 
significantly increased levels of VEGF in patients with MCTD, in whom PAH had been 
diagnosed by RHC (median 371 pg/ml; IQR 277 – 718 pg/ml) compared to MCTD patients 
without PAH (median 159 pg/ml; IQR 120 – 254 pg/ml) (p = 0.005) (Figure 4a). In contrast 
to VEGF, no associations were found between bFGF or endostatin and PAH (p = 0.32 and p = 
0.16, respectively).  
 
Multivariate analysis of clinical parameters and levels of VEGF in MCTD 
Next, we calculated a multivariate linear regression model with these 5 associated 
clinical parameters (acrosclerosis, presence of myositis as defined in methods, increased CK 
levels, PAH by RHC and increased PASP on echocardiography) to predict VEGF levels. In 
addition, lymphadenopathy and rheumatoid factor levels were considered for modeling, since 
they had shown a trend to be associated with VEGF levels in univariate analysis. Also sex and 
age were considered as possible confounders in the regression analysis. The best forward 
selection method led to a model (constant = 71.918) consisting of PAH by RHC (b = 
332.275), increased CK levels (b = 185.485) and lymphadenopathy (b = 325.770). The 
backward selection method led to the same model, which therefore proved to be robust in this 
data set. The correlation coefficient of this model (R = 0. 889) results in a coefficient of 
determination (R2) of 0.791. Thus, these results demonstrate that in patients with MCTD as 
much as 79 % of the variability of the levels of VEGF can be explained by a combination of 
PAH, myositis and lymphadenopathy.  
We also examined cut-off values for the diagnosis of PAH in our patient cohort. VEGF levels 
greater than 270 pg/ml had a sensitivity of 86 % and a specificity of 88 % for PAH in our 
patient collective. Moreover, 94 % of MCTD patients without PAH had VEGF levels below 
366 pg/ml. 
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Discussion 
In the present study, we report for the first time a dysbalance of angiogenic and 
angiostatic mediators in patients with MCTD. VEGF, a potent angiogenic factor that 
stimulates migration, proliferation and survival of endothelial cells and endothelial precursor 
cells was significantly increased in the blood of patients with MCTD. Although the 
upregulation of VEGF appears to be in contrast with the loss of capillaries and the insufficient 
formation in MCTD, it is known that an uncontrolled overexpression of VEGF causes 
deleterious rather than beneficial effects on angiogenesis. Even modestly increased levels of 
VEGF induced by transgenic overexpression of VEGF in mice resulted in a microangiopathy 
that resembled closely the findings in human MCTD and SSc [8]. Thus, the increased levels 
of VEGF might directly contribute to the vascular disease in MCTD. In contrast to SSc, the 
levels of endostatin were also significantly increased in patients with MCTD. A previous 
study also did not find differences in the levels of endostatin in patients with SSc, suggesting 
that the upregulation of endostatin might be specific for MCTD [7]. However, the results for 
endostatin in SSc are inconsistent [18, 19]. Endostatin exerts potent anti-angiogenic effects 
and inhibits endothelial cell migration and proliferation. The upregulation of endostatin might 
thus further perturb the balance between angiogenic and angiostatic growth factors and 
exacerbate the microangiopathy in MCTD. Thus, the combined increase of VEGF and 
endostatin might play a crucial role in the vascular pathogenesis of MCTD. However, a 
limitation of our study is the lack of direct correlations between findings on nailfold 
capillaroscopy and the levels of VEGF and endostatin, which could provide additional support 
of the concept of perturbed angiogenesis in MCTD and needs to be analyzed in further 
studies.  
MCTD is characterized by a spectrum of different clinical manifestations and disease 
severity. Markers predicting the highly variable clinical course and identifying patients at high 
risk for severe disease are currently lacking. Our study provides first evidence that patients 
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with high levels of VEGF might have an increased risk of developing severe disease. High 
levels of VEGF were associated with PAH, the most life-threatening complication of MCTD 
that might occur in a significant percentage of MCTD patients. Consistent with the 
association between VEGF and PAH, increased levels of VEGF were also observed in 
patients with increased PASP on echocardiography. We found that VEGF levels of higher 
than 270 pg/ml had a sensitivity of 86 % and a specificity of 88 % for PAH in our patients. 
This level of accuracy is better than those obtained for echocardiography in patients with SSc 
[20]. Significantly higher levels of VEGF were also observed in MCTD patients with 
myositis. The validity of this association was supported by increased levels of VEGF in 
patients with a history of increased serum levels of CK. The levels of VEGF remained 
elevated in MCTD patients with myositis, even when the myositis was in remission, 
suggesting that increased VEGF may characterize patients with previous myositis rather than 
serve as a marker for myositis activity. These associations between the levels of VEGF and 
PAH and myositis obtained from the univariate analysis were confirmed by the multivariate 
analysis, in which PAH and myositis, together with lymphadenopathy, accounted for as much 
as 79 % of the variability of VEGF levels. Furthermore, the presence of acrosclerosis was also 
associated with increased levels of VEGF, indicating high levels of VEGF might also be a 
feature of the subgroup of MCTD patients with SSc-like manifestations. Although 
confirmation of our results in larger patient cohorts is needed, our study provides the first 
evidence for elevated blood levels of VEGF as a novel risk marker for a more severe, 
potentially life-threatening course of MCTD. These findings may have direct clinical 
implications as those patients likely require close follow-up and monitoring for PAH and 
myositis. 
In summary, we show an uncontrolled overexpression of angiogenic and angiostatic 
factors such as VEGF and endostatin. Furthermore, we demonstrate that high serum levels of 
VEGF are associated with PAH and myositis in MCTD suggesting that increased levels of 
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VEGF might be a potential marker for patients with increased risk for severe, life-threatening 
disease. However, prospective studies with increased numbers of patients are needed for 
confirmation.  
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Tables 
 
     Clinical criteria       Serologic criterion 
1. Puffy hands 
2.   Acrosclerosis with or without  proximal SSc  
3.   Raynaud’s phenomenon 
4.   Myositis: biologically or histologically proven  
5.   Synovitis 
Anti-RNP-antibodies with a 
titre of > 1 : 1600 at the hem-
agglutinin assay 
Diagnosis of MCTD, if the serologic criterion is present and ≥ 3 clinical criteria (if 1, 2 
and 3 are present, 4 and 5 are also required to distinguish MCTD from SSc) 
Table 1: Alarcon-Segovia’s criteria for MCTD 
 
 
        Symptom positive patients 
Puffy hands 25  
Acrosclerosis 18 
Raynaud’s phenomenon 36 
Myositis 21 
Synovitis 30 
PAH 10 
Pulmonary fibrosis 14 
Pleuritis 8 
Pericarditis 9 
Lymphadenopathy 10 
Oesophageal hypomobility 13 
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Trigeminal neuralgia 2 
Leucopenia 10 
Anaemia 13 
Thrombocytopenia 5 
ANA  38 
Rheumatoid factor 21 
anti-Ro-antibodies 6 
anti-Ro-antibodies 1 
anti-dsDNA-antibodies 4 
anti-topoisomerase antibodies 1 
anti-centromer antibodies, anti-PM-Scl 
antibodies, anti-Sm antibodies, anti-
histone-antibodies, anti-PCNA 
antibodies, anti-Jo1 antibodies, anti-
Mi2 antibodies, anti-SRP antibodies, 
anti-AMA antibodies 
 
 
 
all 0  
Table 2: Clinical characteristics of the patients included into the study; n = 38. 
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Figure legends 
Figure 1: Increased levels of VEGF and endostatin in the blood of MCTD patients. The 
serum levels of the angiogenic cytokine VEGF (Figure 1a) as well as the levels of the 
angiostatic factor endostatin (Figure 1b) were significantly increased in patients with MCTD 
compared to age- and sex-matched healthy volunteers. In contrast to MCTD, only the levels 
of VEGF, but not the levels of endostatin, were elevated in patients with lSSc and dSSc 
(Figures 1a and 1b). The levels of VEGF and endostatin are shown as box plots. Each box 
represents the 25th to 75th percentiles. Lines outside the boxes represent the 10th and the 90th 
percentiles. Lines inside the boxes represent the median, circles the outliers, and star the 
extreme values.  
 
Figure 2: Elevated levels of VEGF in MCTD patients with acrosclerosis. Consistent with 
previous reports on increased levels of VEGF in SSc patients, VEGF levels were higher in the 
subset of MCTD patients with acrosclerosis. The levels of VEGF are shown as box plots. 
Each box represents the 25th to 75th percentiles. Lines outside the boxes represent the 10th 
and the 90th percentiles. Lines inside the boxes represent the median, circles the outliers, and 
star the extreme values. 
 
Figure 3: Higher levels of VEGF in patients with myositis. MCTD patients with a history of 
myositis (Figure 3a) or significantly elevated CK (Figure 3b) presented with increased 
serum levels of VEGF compared to MCTD patients without myositis. The levels of VEGF are 
shown as box plots. Each box represents the 25th to 75th percentiles. Lines outside the boxes 
represent the 10th and the 90th percentiles. Lines inside the boxes represent the median, 
circles the outliers, and star the extreme values. 
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Figure 4: Increased levels of circulating VEGF in MCTD patients with PAH. Levels of 
VEGF were significantly higher in MCTD patients diagnosed with PAH by right heart 
catheterization than in those without PAH. The levels of VEGF are shown as box plots. Each 
box represents the 25th to 75th percentiles. Lines outside the boxes represent the 10th and the 
90th percentiles. Lines inside the boxes represent the median, circles the outliers, and star the 
extreme values. 
 
 
 
 
